For research use only. Not for therapeutic Use.
Adrixetinib (TFA) is an inhibitor of protein tyrosine kinase with antineoplastic activity[1][2][3].
| Catalog Number | I040302 |
| Synonyms | N-[5-(6,7-dimethoxyquinolin-4-yl)oxypyridin-2-yl]-1-propyl-4-(2,2,2-trifluoroethoxy)pyrazole-3-carboxamide;2,2,2-trifluoroacetic acid |
| Molecular Formula | C27H25F6N5O7 |
| Purity | ≥95% |
| InChI | InChI=1S/C25H24F3N5O5.C2HF3O2/c1-4-9-33-13-21(37-14-25(26,27)28)23(32-33)24(34)31-22-6-5-15(12-30-22)38-18-7-8-29-17-11-20(36-3)19(35-2)10-16(17)18;3-2(4,5)1(6)7/h5-8,10-13H,4,9,14H2,1-3H3,(H,30,31,34);(H,6,7) |
| InChIKey | JDZQIIDIZOVHIM-UHFFFAOYSA-N |
| SMILES | CCCN1C=C(C(=N1)C(=O)NC2=NC=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)OCC(F)(F)F.C(=O)(C(F)(F)F)O |
| Reference | [1]. WHO Drug Informat ion – World Health Organization (WHO). [2]. Nam Kiyean, et al. Quinoline derivatives as inhibitors of Axl/Mer RTK and CSF1R and their preparation: World Intellectual Property Organization, WO2019229251. 2019-12-05. [3]. WHO Drug Information-World Health Organization (WHO). |
